[A novel antiepileptic, gabapentin (GABAPEN)].
Kunihara
Mineo
M
mineo.kunihara@pfizer.com
Sase
Shinichi
S
Arakawa
Akio
A
D000588:Amines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000927:Anticonvulsants / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D001921:Brain / Q000378:metabolism; D015220:Calcium Channels / Q000378:metabolism; D017326:Clinical Trials, Phase III as Topic; D003509:Cyclohexanecarboxylic Acids / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004828:Epilepsies, Partial / Q000188:drug therapy*; D050485:GABA Plasma Membrane Transport Proteins / Q000378:metabolism; D000077206:Gabapentin; D006801:Humans; D011485:Protein Binding; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use
D000588:Amines; D000927:Anticonvulsants; C425903:CACNA2D1 protein, human; D015220:Calcium Channels; D003509:Cyclohexanecarboxylic Acids; D050485:GABA Plasma Membrane Transport Proteins; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin